DUBLIN, Ireland and BRIDGEWATER, N.J. - Amarin (NASDAQ:AMRN) Corporation plc (NASDAQ:AMRN) today showcased three studies at the American College of Cardiology's 2024 annual meeting, which offer fresh insights into the workings of its cardiovascular drug, VASCEPA/VAZKEPA. The research focuses on the potential effects of Eicosapentaenoic acid (EPA) in combination with high-intensity statins on cardiovascular risk factors.
One study highlighted how the combination of EPA and the statin rosuvastatin could enhance the expression of proteins that detoxify reactive oxygen species in endothelial cells during inflammation. This suggests that the combination might help reduce atherothrombotic risk more than a statin alone.
Another analysis investigated the effects of EPA and rosuvastatin on proteins regulating platelet activity and nitric oxide levels in human endothelial cells. Results indicated that together, these agents might offer greater protection against endothelial dysfunction, which is linked to atherothrombotic risk.
The third study presented at the conference examined EPA's impact on the oxidation of Lipoprotein(a) [Lp(a)], a known cardiovascular disease risk factor. EPA appeared to inhibit Lp(a) oxidation, potentially offering antioxidant benefits that could reduce cardiovascular events.
Amarin's VASCEPA/VAZKEPA, which contains the active ingredient icosapent ethyl, is approved in the United States and various countries for reducing cardiovascular risk in patients with elevated triglycerides who are already on statin therapy.
The findings from these studies build on previous research, including the REDUCE-IT trial, which assessed the effects of VASCEPA in patients with controlled LDL-C and elevated triglycerides, and found a significant reduction in cardiovascular events.
The new data could deepen the understanding of VASCEPA/VAZKEPA's mechanism of action and its potential role in cardiovascular disease management.
This press release statement serves as the basis for the information reported.
InvestingPro Insights
As Amarin Corporation plc (NASDAQ:AMRN) continues to make waves in the cardiovascular health sector with its drug VASCEPA/VAZKEPA, the financial metrics and market indicators provide an additional layer of insight into the company's performance. Amarin's market capitalization stands at $431.21 million, reflecting the market's current valuation of the company.
Investors following Amarin have noted a significant return over the last week, with a price total return of 19.05%. This uptick is part of a broader trend, with the stock also showing strong returns over the last month and three months at 13.75% and 15.91%, respectively. This momentum could be indicative of market optimism surrounding the potential of VASCEPA/VAZKEPA and its recent study results.
However, it's important to note that analysts are anticipating a sales decline in the current year, and the company's revenue growth has decreased by 16.87% over the last twelve months as of Q4 2023. Additionally, Amarin is trading at a low revenue valuation multiple, with a price to book ratio of just 0.78, which could suggest that the stock is undervalued relative to its assets.
For readers looking to delve deeper into Amarin's financials and future prospects, there are additional InvestingPro Tips available. For instance, Amarin holds more cash than debt on its balance sheet and its liquid assets exceed short term obligations, which could be a sign of financial stability. Also, the stock is known for its volatility, which might appeal to certain types of investors. Currently, there are 11 InvestingPro Tips that offer nuanced perspectives on Amarin's financial health and market potential. To explore these insights further and take advantage of the comprehensive analysis, visit https://www.investing.com/pro/AMRN and use the exclusive coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.